44results about How to "Promote hypertrophy" patented technology

The invention provides a Chinese patent medicine for treating prostatitis, which comprises the following raw medicines: aweto, American ginseng, antler, Chinese yam, epimedium, broomrape, Chinese wolfberry, common cnidium fruit, prepared rehmannia root, cynomorium, teasel root, shiandra, angelica, euryale seed, safflower, tuckahoe, moutan bark, rhizoma anemarrhenae, dogwood, dodder, lotus seed, oyster, phellodendron bark, deglued antler, achyranthes, peach kernel, milk vetch, plantain seed and licorice. The Chinese patent medicine is prepared from oral capsules and brewed medicated wine whichare taken together, wherein the oral capsules are taken after breakfast per day, and the brewed medicated wine is drunk at night in the same day. In the invention, the oral capsules and the drinking medicated wine need to be taken together, wherein the oral capsules need to be taken in the morning, and the brewed medicated wine needs to be drunk at night. The Chinese patent medicine provided by the invention can be used for treating both principal and secondary aspects of diseases, can be used for treating prostatitis, conditioning internal secretion and improving sleep quality, has the advantages of short course of treatment, good treatment effect, no side effects and low treatment cost, and is convenient to use. Traditional capsules and medicated wine are adopted in the invention, thus the Chinese patent medicine is convenient to prepare, store and use clinically.

The invention relates to the application of an oral hypoglycemic peptide, which is used for preparing medicine or pharmaceutical composition for treating or preventing diabetes complicated with cardiovascular disease. The oral hypoglycemic peptide is polypeptide OHP2. The polypeptide can effectively improve the myocardial hypertrophy and fibrosis damage caused by diabetes, reduce the content of related myocardial enzymes, regulate the level of lipid metabolism, improve myocardial cell oxidative stress and mitochondrial damage, and thus play a role in protecting the heart. Therefore, the polypeptide can As a candidate molecule for treating or preventing diabetes complicated with cardiovascular disease (especially diabetic cardiomyopathy), it has a good application prospect.

The invention discloses application of a TRAF-associated NF-[Kappa]B activator (TANK) and inhibitors thereof in treatment of cardiac hypertrophy and belongs to the field of functions and application of genes. According to the application, the interrelationship between the expression of a TANK gene and the cardiac hypertrophy is determined; through inhibiting the expression of the TANK, the hypertrophy and fibrosis of cardiac muscles are inhibited remarkably, and cardiac functions are improved; and through promoting the expression of the TANK, the hypertrophy and fibrosis of the cardiac muscles are promoted remarkably, and the cardiac functions are deteriorated. Therefore, the TANK can be used for screening drugs for protecting the cardiac functions, preventing, relieving and / or treating the cardiac hypertrophy and resisting cardiac fibrosis as a drug target, and the inhibitors of the TANK can be used for preparing drugs for protecting the cardiac functions, preventing, relieving and / or treating the cardiac hypertrophy and resisting the cardiac fibrosis.

The invention belongs to the technical field of biomedicine, and particularly relates to the application of CILP2 in the preparation of drugs for improving heart aging and cardiac hypertrophy. The invention takes mice as the experimental object, uses AAV9 virus to overexpress the CILP2 gene at the transcription level, and conducts comparative research by establishing models of cardiac aging and cardiac hypertrophy. The results showed that compared with the aging wild-type control group, overexpression of CILP2 could significantly reduce the levels of aging indicators in the heart of aging mice, reduce the levels of myocardial inflammatory factor indicators in aging mice, and improve the expression levels of myocardial hypertrophy markers. The thickness is reduced, the degree of fibrosis is weakened, and the number of cardiomyocytes is reduced. The above results prove that the expression level of CILP2 can regulate the occurrence of cardiac aging and cardiac hypertrophy, and has a protective effect on cardiac aging and cardiac hypertrophy. Base.